Health-related Quality of Life and costs in Sjögren’s’ syndrome

Research output: Contribution to journalReview articlepeer-review

Standard

Health-related Quality of Life and costs in Sjögren’s’ syndrome. / Miyamoto, Samira; Valim, Valéria; Fisher, Benjamin.

In: Rheumatology (United Kingdom), 15.02.2019.

Research output: Contribution to journalReview articlepeer-review

Harvard

APA

Vancouver

Author

Bibtex

@article{760ab07fb52d4b24aae90cfbe0038c3e,
title = "Health-related Quality of Life and costs in Sj{\"o}gren{\textquoteright}s{\textquoteright} syndrome",
abstract = "Health-related quality of life (HRQoL) has an increasing role in medical decision-making. This review of the literature aims to provide an overview on HRQoL, costs, and work disability in Sj{\"o}gren{\textquoteright}s syndrome (SS), a disease characterized by focal lymphocytic infiltration of exocrine glands with no therapeutics of proven immunomodulatory potential. HRQoL is markedly reduced in SS in multiple studies across many countries when compared with healthy controls. The reduction in HRQoL is similar to that observed in other chronic diseases such as rheumatoid arthritis, systemic lupus erythematosus, fibromyalgia and, interestingly, non-SS sicca syndrome. Impaired HRQoL in SS has been found to be associated with fatigue, pain/articular involvement, ocular and oral involvement, pruritus, sexual dysfunction, impaired sleep, pulmonary manifestations, psychological dysfunction and impaired physical function. Until now no therapeutic has been shown to improve HRQoL in an adequately powered double-blind, placebo-controlled randomized controlled trial. Although pSS does not, in general, impair life expectancy and is often inappropriately considered a benign {\textquoteleft}nuisance{\textquoteright} disease for those patients without systemic manifestations, the associated costs and work disability are striking. This, together with the significant reduction in HRQoL, strongly argues for the development of new therapeutic approaches to manage this neglected disease.",
keywords = "Sj{\"o}gren{\textquoteright}s syndrome, quality of life, health-related quality of life, cost, work disability, SF-36, EQ-5D",
author = "Samira Miyamoto and Val{\'e}ria Valim and Benjamin Fisher",
note = "Samira T Miyamoto, Val{\'e}ria Valim, Benjamin A Fisher; Health-related quality of life and costs in Sj{\"o}gren{\textquoteright}s syndrome, Rheumatology, , key370, https://doi.org/10.1093/rheumatology/key370",
year = "2019",
month = feb,
day = "15",
doi = "10.1093/rheumatology/key370",
language = "English",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "Oxford University Press",

}

RIS

TY - JOUR

T1 - Health-related Quality of Life and costs in Sjögren’s’ syndrome

AU - Miyamoto, Samira

AU - Valim, Valéria

AU - Fisher, Benjamin

N1 - Samira T Miyamoto, Valéria Valim, Benjamin A Fisher; Health-related quality of life and costs in Sjögren’s syndrome, Rheumatology, , key370, https://doi.org/10.1093/rheumatology/key370

PY - 2019/2/15

Y1 - 2019/2/15

N2 - Health-related quality of life (HRQoL) has an increasing role in medical decision-making. This review of the literature aims to provide an overview on HRQoL, costs, and work disability in Sjögren’s syndrome (SS), a disease characterized by focal lymphocytic infiltration of exocrine glands with no therapeutics of proven immunomodulatory potential. HRQoL is markedly reduced in SS in multiple studies across many countries when compared with healthy controls. The reduction in HRQoL is similar to that observed in other chronic diseases such as rheumatoid arthritis, systemic lupus erythematosus, fibromyalgia and, interestingly, non-SS sicca syndrome. Impaired HRQoL in SS has been found to be associated with fatigue, pain/articular involvement, ocular and oral involvement, pruritus, sexual dysfunction, impaired sleep, pulmonary manifestations, psychological dysfunction and impaired physical function. Until now no therapeutic has been shown to improve HRQoL in an adequately powered double-blind, placebo-controlled randomized controlled trial. Although pSS does not, in general, impair life expectancy and is often inappropriately considered a benign ‘nuisance’ disease for those patients without systemic manifestations, the associated costs and work disability are striking. This, together with the significant reduction in HRQoL, strongly argues for the development of new therapeutic approaches to manage this neglected disease.

AB - Health-related quality of life (HRQoL) has an increasing role in medical decision-making. This review of the literature aims to provide an overview on HRQoL, costs, and work disability in Sjögren’s syndrome (SS), a disease characterized by focal lymphocytic infiltration of exocrine glands with no therapeutics of proven immunomodulatory potential. HRQoL is markedly reduced in SS in multiple studies across many countries when compared with healthy controls. The reduction in HRQoL is similar to that observed in other chronic diseases such as rheumatoid arthritis, systemic lupus erythematosus, fibromyalgia and, interestingly, non-SS sicca syndrome. Impaired HRQoL in SS has been found to be associated with fatigue, pain/articular involvement, ocular and oral involvement, pruritus, sexual dysfunction, impaired sleep, pulmonary manifestations, psychological dysfunction and impaired physical function. Until now no therapeutic has been shown to improve HRQoL in an adequately powered double-blind, placebo-controlled randomized controlled trial. Although pSS does not, in general, impair life expectancy and is often inappropriately considered a benign ‘nuisance’ disease for those patients without systemic manifestations, the associated costs and work disability are striking. This, together with the significant reduction in HRQoL, strongly argues for the development of new therapeutic approaches to manage this neglected disease.

KW - Sjögren’s syndrome

KW - quality of life

KW - health-related quality of life

KW - cost

KW - work disability

KW - SF-36

KW - EQ-5D

U2 - 10.1093/rheumatology/key370

DO - 10.1093/rheumatology/key370

M3 - Review article

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

ER -